bepotastine immediate release / Generic mfg. - LARVOL DELTA

Effects of Second-generation Antihistamine Bepotastine on Cough Outcomes in Cough Patients With Allergic Rhinitis (clinicaltrials.gov) - P4 | N=50 | Completed | Sponsor: Asan Medical Center | Not yet recruiting ➔ Completed | N=78 ➔ 50 | Trial primary completion date: Jun 2022 ➔ Sep 2022

Enrollment change • Trial completion • Trial primary completion date • Allergic Rhinitis • Cough • Immunology • Inflammation • Respiratory Diseases

Effects of Second-generation Antihistamine Bepotastine on Cough Outcomes in Cough Patients With Allergic Rhinitis (clinicaltrials.gov) - P4; N=78; Not yet recruiting; Sponsor: Asan Medical Center; Initiation date: May 2021 ➔ Oct 2021

Clinical • Trial initiation date • Allergic Rhinitis • Immunology • Respiratory Diseases

Effects of Second-generation Antihistamine Bepotastine on Cough Outcomes in Cough Patients With Allergic Rhinitis (clinicaltrials.gov) - P4; N=78; Not yet recruiting; Sponsor: Asan Medical Center

Clinical • New P4 trial • Allergic Rhinitis • Immunology • Respiratory Diseases

To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital. (PubMed, Indian J Pharmacol) - "In this study, based on the evaluation of therapeutic performance, bepotastine eye drops proved quicker relief of symptoms and signs compared to olopatadine eye drops but was not statistically significant which would prove beneficial for the patients."

Clinical • Journal • Allergy • Conjunctivitis • Dry Eye Disease • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology

Efficacy and Toxicity of Bepotastine Besilate 1,5% Preservative Free vs Olopatadine Hydrochloride 0,2% With BAK on Allergic Conjunctivitis Treatment (clinicaltrials.gov) - P4; N=100; Not yet recruiting; Sponsor: Laboratorios Poen

Clinical • Head-to-Head • New P4 trial • Conjunctivitis • Ocular Inflammation • Ophthalmology

Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis. (PubMed, Indian J Ophthalmol) - "All three topical ophthalmic medications used in the study are safe and effective in the treatment of allergic conjunctivitis. However, Bepotastine and Alcaftadine appear to outweigh Olopatadine in resolving the symptoms of allergic conjunctivitis."

Clinical • Journal • Conjunctivitis • Ocular Inflammation • Ophthalmology

Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+ (clinicaltrials.gov) - P1; N=22; Completed; Sponsor: Laboratorios Sophia S.A de C.V.

Clinical • New P1 trial • Ophthalmology

[VIRTUAL] OCCUPATIONAL EXPOSURE TO MANGOS AND CROSS-REACTIVITY (ACAAI 2020) - "His current rash failed to improve with Dexamethasone IM, Medrol Dose pack, Triamcinolone Acetonide, steroid eye drops, and antihistamines. Allergy team advised the patient to avoid scratching his face, continue with topical steroid creams, finish current Medrol dose pack, use Bepotastine eye drop and moisturize hands...Correlation of history, presentation and exposure provide opportunities for effective diagnosis, treatment and prevention. Similarly, increased awareness of future hypersensitivity reaction can promote risk mitigation and guide employment decisions."

Allergy • Immunology

Double-Blind Placebo-Controlled Trial of Bepotastine Salicylate in Patients With Allergic Rhinitis. (PubMed, Laryngoscope) - "This multicenter trial showed that once-daily use of HL151 is efficacious and safe in adult patients with PAR and could improve compliance due to its convenience."

Clinical • Journal • Allergic Rhinitis • Allergy • Hepatitis B • Immunology • Infectious Disease • Pruritus

Identification, Characterization and HPLC Quantification of Process-Related Impurities in Bepotastine Besilate Bulk Drug. (PubMed, Drug Res (Stuttg)) - "It is the first publication of identification and characterization data of the 3 new compounds. It is also the first effective HPLC method for separation and quantification of all of process-related impurities in bepotastine besilate."

Journal

Drug Interaction Study Between Erdosteine and Bepotastine Besilate in Healthy Adult Volunteers (clinicaltrials.gov) - P1; N=36; Completed; Sponsor: Daewoong Pharmaceutical Co. LTD.

New P1 trial • Biosimilar • Immunology • Inflammation

"Added benefit of Bepreve is that it also reduces itching and running nose." (@DarrellWhite)

The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer (clinicaltrials.gov) - P4; N=40; Completed; Sponsor: Minnesota Eye Consultants, P.A.; Active, not recruiting ➔ Completed

Trial completion

Characterization of photodegradation products of bepotastine besilate and in silico evaluation of their ADMET properties. (PubMed, J Pharm Sci) - "One degradation product had a structure that could only be explained by unusual rearrangement involving conversions of N-oxide into hydroxylamine, similar to Meisenheimer rearrangement. The physicochemical, as well as absorption, distribution, metabolism, excretion and toxicity properties of BPT and its characterized photodegradation products were evaluated in silico by ADMET Predictor™ software."

Journal

Comparison of cytotoxicities and anti-allergic effects of topical ocular dual-action anti-allergic agents. (PubMed, BMC Ophthalmol) - "Alcaftadine seems to have less side effects and better therapeutic effects than the other two anti-allergic agents tested. It may be more beneficial to use less toxic agents for patients with ocular surface risk factors or presumed symptoms of toxicity."

Journal

Bioequivalence Test of "Dong-a Bepotastine Besilate Tab" and "Twolion Tab" (clinicaltrials.gov) - P=N/A; N=32; Completed; Sponsor: Dong-A ST Co., Ltd.; Recruiting ➔ Completed

Clinical • Trial completion

Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis. (PubMed, Indian J Ophthalmol) - "Few cases with limbal or palpebral papillae reported symptomatic relief after use of medication, but the resolution of these signs was not noted in all three groups. We concluded similar efficacy of three medications in relieving symptoms and inefficacy in regressing palpebral and limbal papillae in cases of allergic conjunctivitis."

Clinical • Journal

Efficacy and adverse effects of bepotastine as compared to fexofenadine in allergic rhinitis (NAPCON 2019) - "Bepotastine gives comparable symptom control and has similar adverse effect profile compared to fexofenadine."

Adverse events • Clinical

Bioequivalence Test of "Dong-a Bepotastine Besilate Tab" and "Twolion Tab" (clinicaltrials.gov) - P=N/A; N=32; Recruiting; Sponsor: Dong-A ST Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Bioequivalence Test of "Dong-a Bepotastine Besilate Tab" and "Twolion Tab" (clinicaltrials.gov) - P=N/A; N=32; Not yet recruiting; Sponsor: Dong-A ST Co., Ltd.

Clinical • New trial